 TransMedics Group, Inc. has a 205M in cash compared to 68M in debt and recently reported net revenue of 25.7M for Q3 22, representing a 378 increase compared to the Q3 21. OCS Kidney, the companys fourth product, is set to begin clinical trials in early 2023. 